Comparative Pharmacology
Head-to-head clinical analysis: JANUMET XR versus JENTADUETO XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUMET XR versus JENTADUETO XR.
JANUMET XR vs JENTADUETO XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JANUMET XR is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases active incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
One tablet orally once daily, with evening meal; initial dose based on patient's current sitagliptin and metformin doses, or new patients: starting dose 50 mg sitagliptin/500 mg metformin XR; maximum dose 100 mg sitagliptin/2000 mg metformin XR per day.
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
None Documented
None Documented
Sitagliptin: terminal half-life ~12.4 hours, allowing once-daily dosing. Metformin: terminal half-life ~6.2 hours in plasma, increased to ~17.6 hours in renal impairment.
Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Sitagliptin: ~79% excreted unchanged in urine via renal tubular secretion (active secretion) and glomerular filtration; ~13% undergoes hepatic metabolism; ~1% excreted in feces. Metformin: ~90% excreted unchanged in urine via active tubular secretion.
Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Category C
Category C
DPP-4 Inhibitor/Biguanide Combination
DPP-4 Inhibitor / Biguanide Combination